Sinocelltech Group Ltd
SSE:688520
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
31.32
54.1
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Sinocelltech Group Ltd
Sinocelltech Group Ltd
Cash from Investing Activities
Sinocelltech Group Ltd
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sinocelltech Group Ltd
SSE:688520
|
Cash from Investing Activities
-¥502.8m
|
CAGR 3-Years
-68%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Cash from Investing Activities
¥117.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Cash from Investing Activities
-¥2.3B
|
CAGR 3-Years
20%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cash from Investing Activities
-¥2.1B
|
CAGR 3-Years
-91%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cash from Investing Activities
-¥1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-18%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cash from Investing Activities
-¥1.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-102%
|
CAGR 10-Years
N/A
|
|
Sinocelltech Group Ltd
Glance View
Sinocelltech Group Ltd. has carved a distinct niche within the biopharmaceutical industry, positioning itself as a leading innovator in the development of biologics. The company, based in China, specializes in the research, production, and commercialization of therapeutic and preventative vaccines, antibodies, and recombinant proteins. By leveraging advanced biotechnology platforms, Sinocelltech navigates the complex landscape of biologic drug development, focusing on high-potential therapeutic areas such as oncology, autoimmune diseases, and infectious diseases. Its strategic move to integrate research and production capabilities allows it to maintain tight control over the quality and scalability of its products, providing a competitive edge in the highly regulated and rapidly evolving biotech sector. At the heart of Sinocelltech's business model lies its ability to generate revenue by bringing innovative biologics from the lab to the market—either independently or through strategic partnerships and collaborations. The company capitalizes on its robust pipeline of biologic candidates, some of which have already received market approval and are generating sales both domestically and internationally. Furthermore, Sinocelltech earns revenue from licensing its proprietary technologies and manufacturing capabilities to other pharmaceutical companies, which seek efficient pathways to develop their biologics. This diversified approach not only stabilizes its revenue streams but also reinforces its reputation as a formidable player in the global biopharmaceutical arena.
See Also
What is Sinocelltech Group Ltd's Cash from Investing Activities?
Cash from Investing Activities
-502.8m
CNY
Based on the financial report for Dec 31, 2023, Sinocelltech Group Ltd's Cash from Investing Activities amounts to -502.8m CNY.
What is Sinocelltech Group Ltd's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
-39%
Over the last year, the Cash from Investing Activities growth was 8%. The average annual Cash from Investing Activities growth rates for Sinocelltech Group Ltd have been -68% over the past three years , -39% over the past five years .
You don't have any saved screeners yet
